<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16614">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01856309</url>
  </required_header>
  <id_info>
    <org_study_id>CR102023</org_study_id>
    <secondary_id>CNTO136ARA3004</secondary_id>
    <secondary_id>2012-001176-10</secondary_id>
    <nct_id>NCT01856309</nct_id>
  </id_info>
  <brief_title>Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003</brief_title>
  <acronym>SIRROUND-LTE</acronym>
  <official_title>A Multicenter, Parallel-group Study of Long-term Safety and Efficacy of CNTO 136 (Sirukumab) for Rheumatoid Arthritis in Subjects Completing Treatment in Studies CNTO136ARA3002 (SIRROUND-D) and CNTO136ARA3003 (SIRROUND-T)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the long-term safety and efficacy of CNTO 136
      (sirukumab) in participants with rheumatoid arthritis (RA) who are unresponsive to treatment
      with modifying antirheumatic drugs (DMARDs) or anti-TNF alpha agents.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, long-term study of sirukumab (CNTO 136) that will be conducted in two
      groups of participants at the same time (parallel-group study).  The maximum duration of
      participation in this study is 208 weeks, followed by approximately 16 weeks of safety and
      efficacy follow-up after the administration of the final study agent injection of sirukumab.
       Participant safety will be monitored throughout the study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The number of participants with cardiovascular serious adverse events (SAEs)</measure>
    <time_frame>Up to 224 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>The number of participants with malignancies</measure>
    <time_frame>Up to 224 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>The number of participants with serious infections</measure>
    <time_frame>Up to 224 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>The number of participants with gastrointestinal perforations</measure>
    <time_frame>Up to 224 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Observations of laboratory parameters of interest (neutrophils, platelets, hepatobiliary parameters, and lipid parameters)</measure>
    <time_frame>Up to 224 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of toxicity grading</measure>
    <time_frame>Up to 224 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who achieve ACR 20 response</measure>
    <time_frame>Up to 208 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>American College of Rheumatology (ACR) 20 response is a &gt;=20% improvement in rheumatoid arthritis (RA) symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who achieve ACR 50 response</measure>
    <time_frame>Up to 208 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>ACR 50 response is a &gt;=50% improvement in RA symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who achieve ACR 70 response</measure>
    <time_frame>Up to 208 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>ACR 70 response is a &gt;=70% improvement in RA symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with DAS28 (CRP) response</measure>
    <time_frame>Up to 208 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>DAS28 (using CRP [C-reactive protein]) response is improvement from baseline, with &gt;1.2 indicating a good or moderate response and &lt;=0.6 indicating no response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with DAS28 (CRP) remission</measure>
    <time_frame>Up to 208 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>DAS28 (using CRP [C-reactive protein]) remission is defined as a value of &lt;2.6 on the Disease Activity Index, a measure of tender and swollen joints and the patient's assessment of disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in DAS28 (CRP)</measure>
    <time_frame>Up to 208 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>DAS28 (using CRP [C-reactive protein]) is a measure of tender and swollen joints and the patient's assessment of disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with SDAI-based ACR/EULAR remission</measure>
    <time_frame>Up to 208 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Simplified Disease Activity Index (SDAI)-based ACR/EULAR (European League Against Rheumatism) remission is defined as a SDAI value of &lt;=3.3 at a visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with Boolean-based ACR/EULAR remission</measure>
    <time_frame>Up to 208 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Boolean-based ACR/EULAR remission is achieved if all of the following 4 criteria at that visit are met: tender joint count (68 joints) &lt;=1; swollen joint count (66 joints) &lt;= 1; CRP &lt;=1 mg/dL; and Patient's Global Assessment of Disease Activity on VAS &lt;=1 on a 0 to 10 scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in SDAI</measure>
    <time_frame>Up to 208 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Simplified Disease Activity Index (SDAI) score is a derived score combining tender joints (28 joints), swollen joints (28 joints), Patient's Global Assessment of Disease Activity, Physician's Global Assessments of Disease Activity, and CRP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in CDAI</measure>
    <time_frame>Up to 208 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical Disease Activity Index (CDAI) score is a derived score combining tender joints (28 joints), swollen joints (28 joints), Patient's Global Assessment of Disease Activity, and Physician's Global Assessments of Disease Activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in HAQ-DI</measure>
    <time_frame>Up to 208 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Health Assessment Questionnaire-Disability Index (HAQ-DI) assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas, each scored from 0 (no difficulty) to 3 (inability to perform a task).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of HAQ-DI responders (ie, those who have a change from baseline of &gt; 0.22 in HAQ-DI score)</measure>
    <time_frame>Up to 208 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Health Assessment Questionnaire-Disability Index (HAQ-DI) assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas, each scored from 0 (no difficulty) to 3 (inability to perform a task).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Physical Component Score (PCS)</measure>
    <time_frame>Up to 208 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Physical Component Score is a summary score with higher scores indicating better health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Mental Component Score (MCS)</measure>
    <time_frame>Up to 208 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Mental Component Score is a summary score with higher scores indicating better health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in domain scores of 36-item short form health survey (SF-36)</measure>
    <time_frame>Up to 208 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The SF-36 is a medical outcome study health measure and consists of 8 multi-item scales that are scored from 0 to 100, with higher scores indicating better health.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2165</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Sirukumab 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sirukumab 50 mg / placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirukumab 100 mg</intervention_name>
    <description>Sirukumab 100 mg subcutaneously (SC) at Weeks 0 (administered as the last dose in CNTO136ARA3002 or CNTO136ARA3003), 2, and every 2 weeks through Week 156 for participants who completed CNTO136ARA3002 and through Week 208 for participants who completed CNTO136ARA3003.</description>
    <arm_group_label>Sirukumab 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirukumab 50 mg</intervention_name>
    <description>Sirukumab 50 mg SC at Weeks 0 (administered as the last dose in CNTO136ARA3002 or CNTO136ARA3003), 4, and every 4 weeks through Week 156 for participants who completed CNTO136ARA3002 and through Week 208 for participants who completed CNTO136ARA3003.</description>
    <arm_group_label>Sirukumab 50 mg / placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Between sirukumab 50 mg injections, placebo SC injections will be administered at Weeks 2, 6, and every 4 weeks until the study becomes open-label, and placebo injections are discontinued.</description>
    <arm_group_label>Sirukumab 50 mg / placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Completed participation in Studies CNTO136ARA3002 or CNTO136ARA3003

          -  Signed an informed consent form (ICF) indicating that they understand the purpose of
             and procedures required for the study and are willing to participate in the study

          -  Signed an informed consent form (ICF) for pharmacogenetics research (how a person's
             genes may affect a drug's effects) in order to participate in the optional
             pharmacogenetics component of this study. Refusal to give consent for this component
             does not exclude a participant from participation in this clinical study

        Exclusion Criteria:

          -  Withdraws consent and/or discontinues participation in study CNTO136ARA3002 or
             CNTO136ARA3003

          -  Is pregnant

          -  Has active diverticulitis

          -  Has any condition that, in the opinion of the investigator, would make participation
             not be in the best interest (eg, compromise the well-being) of the participant or
             that could prevent, limit, or confound the protocol-specified assessments
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Use link at the bottom of the page to see if you qualify for an enrolling site (see list). If you still have questions:</last_name>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Cerritos</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Lakewood</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Victorville</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Debary</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Zephyrhills</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Cedar Rapids</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Freehold</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Edmond</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Beckley</city>
        <state>West Virginia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Quilmes</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Ixelles</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Schwerin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Zerbst</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kagoshima</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kato</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagasaki</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagoya</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Shimotsuke</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Shinjuku-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Sumida-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Takaoka,Toyama</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Takasaki</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Ureshino</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Guadalajara, Jalisco</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Barnaul</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Coru√±a</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago De Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Changhua</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Taichung City</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Ternopil</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Dorset</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Essex</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Argentina</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://pam.sylogent.com/cr/CR102023</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 22, 2014</lastchanged_date>
  <firstreceived_date>May 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Sirukumab</keyword>
  <keyword>CNTO 136</keyword>
  <keyword>CNTO136ARA3002</keyword>
  <keyword>SIRROUND-D</keyword>
  <keyword>CNTO136ARA3003</keyword>
  <keyword>SIRROUND-T</keyword>
  <keyword>SIRROUND-LTE</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
